Shots:

• Dupixent’s US label has been updated for its use in 12yrs. and older atopic dermatitis patients with uncontrolled moderate-to-severe hand and/or foot involvement
• The update was supported by the results from P-III (LIBERTY-AD-HAFT) study assessing Dupixent (n=67; adults: 300mg, adolescents: 200mg/300mg based on body weight, Q2W) vs PBO (n=66) in total 133 atopic dermatitis patients with moderate-to-severe hand and/or foot involvement who had insufficient response or intolerance to topical corticosteroids
• The results at 16wks. demonstrated that 52% experienced reduced itch vs 14% and 40% of them attained clear/almost clear skin vs 17% with PBO on hands and feet

Ref: Globe Newswire | Image: Sanofi

Related News:- Sanofi Reports Results for Dupixent in P-III Trial for the Treatment of Patients with COPD

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com